

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 5233

WILLIAM S. DOWNEY, JR., M.D.
237 UNION STREET
NEW BEDFORD, MASS. 02740
TEL. (617) 892-1442

February 5, 1969

Dr. Paul Bryan
Special Assistant for Drug Efficacy Study Implementation
Bureau of Medicine
Food & Drug Administration
200 C Street, S.W.
Washington, D.C. 20204

Dear Dr. Bryan:

I am responding to a letter from J.C. Gauntlett of the Upjohn Company to write to you about the misleading statements that have been in the newspapers about Panalba and Mystecilin. I had several patients who called me and questioned why I had used Panalba and Mystecilin on previous occasions and what kind of a doctor would use a medicine that was ineffective or no good. Without having all the material available to me that you have available to you, it still does not seem to be the most effective way for all concerned to have a statement in the newspapers suggesting that a preparation which is commercially available is ineffective when in truth, there is some effectiveness.

I am not and never have been a big user of Panalba and Mystecilin, but there are times when I find them effective. Panalba is effective for me in cases of croup and we have many cases of croup in our area. I use Mystecilin F when I have a newborn child who could use a broad spectrum preparation and I don't want to run the risk of developing thrush.

As a result of the public statements on these two preparations, when I write for them I run the risk of someone picking this up and recognizing the names and saying, "Isn't that the drug that the Federal Government has withdrawn?" I would like to add my name to the list of those who are protesting.

Sincerely,

William S. Downey, Jr.

William S. Downey, Jr. M.D.

RECEIVED

FEB 10 1969

WSD/ja DRUG EFFICACY STUDY
IMPLEMENTATION
TICK FORGE

15-10